相关实验视频
Updated: Jun 23, 2025
07:44
A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
334
Xe/O2吸入对实验性血栓状质体肺炎中的血液静止的影响
E P Fedorova1,2, M V Filonova3,4, A A Churin3,4
1E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia. fedorova-elen@mail.ru.
Bulletin of experimental biology and medicine
|June 21, 2024
概括
吸入/氧 (Xe/O2) 混合物有效降低了实验性肺炎中的炎症. 这种疗法还改善了血液凝结标志物,包括前血时间和抗血III活性.
科学领域:
- 肺部医学 肺部医学
- 麻醉学 麻醉学
- 生物化学 生物化学
背景情况:
- 血栓塑素诱导的肺炎是一种炎症性肺部疾病.
- 这个模型在气体交换和血液凝结方面提出了挑战.
研究的目的:
- 评估在实验性肺炎中吸入/氧 (Xe/O2) 混合物的治疗疗效.
- 评估Xe/O2对炎症标志物和血液凝结的影响.
主要方法:
- 试验性血栓塑性肺炎的麻醉动物每天接受30% Xe/70% O2 混合物治疗,每天20分钟,持续5天.
- 测量了炎症标志物 (温度,肺重量) 和血液凝固参数 (前热血素时间,激活的部分血栓塑时间,纤维素,抗热血素III).
主要成果:
- 吸入 Xe/O2 显著降低了肺炎,体现为温度反应降低和肺部体重正常化.
- 治疗使前列血时间正常化,并激活了部分血栓塑时间,纤维素生成量中等程度下降.
- 从第5天到第14天,抗凝血素III活性显著增加,表明抗凝血剂功能的增强.
结论:
- 吸入 Xe/O2 在实验性肺炎中显示出强大的抗炎作用.
- 这种治疗方法也有益地调节了血液凝固系统,改善了血液静止和抗凝能力.
相关概念视频
01:26Pneumothorax-I
194
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
194
01:27Pneumothorax-II
139
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
139